Advances in the treatment of chronic hepatitis C: Update to the Committee

12/20/01


Click here to start


Table of Contents

Advances in the treatment of chronic hepatitis C: Update to the Committee

Treating chronic hepatitis C 10 years of progress

Advancements in the treatment of chronic hepatitis C Participant Introduction

PPT Slide

Treatment chronic hepatitis C Information provided to the committee

The PEG-Intron molecule

Intron A 3MU TIW Sustained virologic response by patient weight

PPT Slide

PEG-Intron monotherapy virologic response

PEG-Intron monotherapy virologic response

PEG-Intron monotherapy Factors Associated with Sustained Virologic Response*

PEG-Intron dose selection

PEG-Intron plus Rebetol

Demographics

Disease Characteristics

Sustained Virologic Response

Sustained Virologic Response

PPT Slide

Effect of Rebetol dose mg/kg on virologic response (Logistic regression analysis)

All genotypes Sustained virologic response Controlling for Rebetol dose (mg/kg)

HCV-1 Sustained virologic response Controlling for Rebetol dose (mg/kg)

HCV-2/3 Sustained virologic response Controlling for Rebetol dose (mg/kg)

Sustained virologic response Controlling for Rebetol dose (mg/kg)

Relapse Controlling for Rebetol dose and genotype

PPT Slide

PEG-Intron/Rebetol Safety

PPT Slide

Discontinuations and dose modifications due to adverse events

Dose modification ɮ% difference between groups

PPT Slide

Adverse hematologic effects Hemoglobin

Safety Summary

PPT Slide

Dr. J. McHutchison

The Decision to Treat Hepatitis C

Weighing the Risks and Benefits

Decision to Treat

Decision to Treat Hepatitis C

How can we achieve the greatest benefit whilst diminishing the risk?

Author: Alexander Strunc